Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Treasury Shares: 2014-2025

Historic Treasury Shares for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Sep 2025 value amounting to $387.7 million.

  • Amphastar Pharmaceuticals' Treasury Shares rose 33.33% to $387.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $387.7 million, marking a year-over-year increase of 33.33%. This contributed to the annual value of $332.7 million for FY2024, which is 34.47% up from last year.
  • Amphastar Pharmaceuticals' Treasury Shares amounted to -$15.3 million in Q3 2025, which was down 1.12% from -$15.2 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Treasury Shares ranged from a high of $1.3 million in Q3 2023 and a low of -$15.3 million during Q3 2025.
  • For the 3-year period, Amphastar Pharmaceuticals' Treasury Shares averaged around -$9.3 million, with its median value being -$11.5 million (2024).
  • Data for Amphastar Pharmaceuticals' Treasury Shares shows a peak YoY spiked of 49.67% (in 2025) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Treasury Shares (Quarterly) stood at $150.5 million in 2021, then grew by 25.95% to $189.5 million in 2022, then surged by 30.55% to $247.4 million in 2023, then surged by 34.47% to $332.7 million in 2024, then spiked by 33.33% to $387.7 million in 2025.
  • Its last three reported values are $387.7 million in Q3 2025, $382.8 million for Q2 2025, and $343.9 million during Q1 2025.